Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT06056583 · ClinicalTrials.gov registry record · Phase 4

Drug Excretion in Breast Milk

A Phase 4 study of Postpartum and Lactation, sponsored by University of Washington.

Recruiting
Registry status
Phase 4
Development phase
50
Enrollment target
1
Study location

NCT06056583 is a Phase 4 study of Postpartum and Lactation that is actively recruiting participants, run by University of Washington. The registered enrollment target is 50 participants, below the 248-participant average among 16 other Postpartum trials with a reported enrollment target (80% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT06056583, a Phase 4 study of Postpartum and Lactation, is actively recruiting participants, sponsored by University of Washington.

RECRUITING
Registry status
Phase 4
Development phase
50 participants
Enrollment target
1
Study location

Study Summary

This is a prospective, non-randomized, phase I study design evaluating the in vivo activities and expression of OCT1 and BCRP in mammary gland of lactating women at three time points postpartum.

Interventions

  • DRUG Cimetidine 200 MG

Study Locations (1)

Washington

  • University of Washington - Seattle

Trial Details

FieldValue
Enrollment Target 50 participants
Start Date 2023-12-04
Est. Completion 2028-09-30
Phase Phase 4

Sponsor

University of Washington

1,048 total trials

What the Registry Record Tells You About NCT06056583

The ClinicalTrials.gov registry entry for NCT06056583 describes a study currently listed as recruiting, categorized as Phase 4. The registered enrollment target is 50 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 248-participant average among 16 other Postpartum trials with a reported enrollment target (80% lower). The listed sponsor is University of Washington, which has 1,048 total studies on file at ClinicalTrials.gov.

The record links to 6 conditions, with Postpartum appearing as the primary indexed condition, and to 1 intervention - of which Cimetidine 200 MG is the first listed.

NCT06056583 reports 1 study location spanning 1 distinct geographic area - top geographies include Washington.

Frequently Asked Questions

What is clinical trial NCT06056583 about?

NCT06056583 is a clinical study titled "Drug Excretion in Breast Milk". This is a prospective, non-randomized, phase I study design evaluating the in vivo activities and expression of OCT1 and BCRP in mammary gland of lactating women at three time points postpartum.

What is the current status of trial NCT06056583?

This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 50 participants. The study started on 2023-12-04. Estimated completion is 2028-09-30.

What conditions does trial NCT06056583 study?

This clinical trial studies the following conditions: Postpartum, Lactation, Drugs in Breast Milk, Mammary Drug Transporters, BCRP.

What interventions are being tested in trial NCT06056583?

The interventions under investigation include: Cimetidine 200 MG (DRUG).

Who is sponsoring clinical trial NCT06056583?

This trial is sponsored by University of Washington, which has 1,048 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT06056583 being conducted?

This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Postpartum

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.